

eTable 3. Comparing the associations of hydroxyzine use and zopiclone use with the endpoint of death in the full sample and in the matched analytic sample.

	Number of events / Number of patients	Crude Cox regression analysis	Multivariable Cox regression analysis	Analysis weighted by inverse- probability- weighting weights	Number of events / Number of patients	Univariate Cox regression in the matched analytic sample (1:1)
	N (%)	HR (95% CI; p- value)	HR (95% CI; p- value) (df=24)	HR (95% CI; p- value)	N (%)	HR (95% CI; p- value)
Zopiclone	46 / 151 (30.5%)	Ref.	Ref.	Ref.	4 / 12 (33.3%)	Ref.
Hydroxyzine	14 / 129 (10.9%)	0.38 (0.21 - 0.70; 0.002*)	0.39 (0.21 – 0.73; 0.003*)	0.32 (0.15 – 0.70; 0.004*)	14 / 129 (10.9%)	0.27 (0.09 – 0.83; 0.022*)
Hydroxyzine and Zopiclone	1 / 9 (1.1%)	0.27 (0.04 - 2.00; 0.201)	0.29 (0.04 – 2.43; 0.255)	0.06 (0.01 – 0.49; 0.009*)	1 / 9 (1.1%)	0.19 (0.02 – 1.68; 0.135)
No hydroxyzine or Zopiclone	933 / 7056 (13.2%)	0.61 (0.45 - 0.82; 0.001*)	0.85 (0.62 – 1.16; 0.305)	0.74 (0.51 – 1.08; 0.116)	49 / 264 (18.6%)	0.61 (0.22 – 1.70; 0.349)

* p-value is significant (p<0.05).